



Repair Therapeutics to Host Investor and Analyst Conference Call and Webcast

November 7, 2023

Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Nov. 7, 2023-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Pol θ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.

Conference Call and Webcast Details:

To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repair Therapeutics call. A live webcast will be available in the Investor section of the Company's website at <https://ir.reparerx.com/events-and-presentations/events>. A webcast replay will also be archived for at least 30 days.

About Repair Therapeutics, Inc.

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx $\text{\textcircled{R}}$ platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Pol θ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx $\text{\textcircled{R}}$ is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231107600865/en/): <https://www.businesswire.com/news/home/20231107600865/en/>

Repair:

Steve Forte
Executive Vice-President and Chief Financial Officer
Repair Therapeutics Inc.
investor@reparerx.com

Investors:

Matthew DeYoung
Argot Partners
repair@argotpartners.com

Media:

David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902

Source: Repair Therapeutics Inc.